Table 1. Patient characteristics (a) without BM and (b) with BM as first site of progression.
| (a) | |||
|---|---|---|---|
|
Entered patients (n=169)
|
|||
| Characteristics | n | % | |
| Median age at first diagnosis (years) | 50 | ||
| Range | 25–82 | ||
| Age >65 years | 17 | 10.1 | |
| Age <35 years | 17 | 10.1 | |
| Grade 3 tumour | 116 | 73.9 | |
| Invasive ductal carcinoma | 135 | 87.1 | |
| Stage IV | 32 | 18.9 | |
| Subtype | |||
| Luminal subtype | 36 | 21.3 | |
| HER-2 subtype | 102 | 60.4 | |
| Triple-negative subtype | 31 | 18.3 | |
| Adjuvant chemotherapy | 115 | 83.9 | |
| Adjuvant endocrine therapy | 53 | 38.1 | |
| Adjuvant trastuzumab | 12 | 8.8 | |
| Median time to progression (months) | 22 | ||
| Range | 0–166 | ||
| Visceral metastases | 121 | 72.0 | |
| Brain as the first site of metastatic disease | 0 | 0 | |
| Median metastatic sites | 2 | ||
| Range | 1–5 | ||
| Lung | 79 | 47.0 | |
| Liver | 71 | 42.3 | |
| Bones | 81 | 48.2 | |
| Lymph nodes | 48 | 28.6 | |
| Soft tissue | 54 | 32.1 | |
| Skin | 17 | 10.1 | |
| Others | 11 | 6.6 | |
| Palliative chemotherapy before BM | 152 | 89.9 | |
| Palliative endocrine therapy before BM | 63 | 37.5 | |
| Palliative trastuzumab before BM | 85 | 50.3 | |
| Palliative lapatinib before BM | 2 | 1.2 | |
| Response to systemic therapy at time of BM diagnosis | |||
| CR | 3 | 3.3 | |
| PR | 29 | 31.9 | |
| SD | 32 | 35.2 | |
| PD | 27 | 29.7 | |
| Median BM free survival (months) | 19 | ||
| Range | 1–170 | ||
| Median OS from first diagnosis (months) | 58.5 | ||
| Range | 3–218 | ||
| Median OS from diagnosis of metastatic disease | 33 | ||
| Range | 2–125 | ||
| Median OS from diagnosis of BM (months) | 5.5 | ||
| Range | 0–81 | ||
| (b) | |||
|
Entered patients (n=44)
|
|||
| Characteristics | n | % | |
| Median age at first diagnosis (years) | 54 | ||
| Range | 27–79 | ||
| Age >65 years | 5 | 11.4 | |
| Age <35 years | 4 | 9.1 | |
| Grade 3 tumour | 31 | 75.6 | |
| Invasive ductal carcinoma | 30 | 73.2 | |
| Stage IV | 4 | 9.1 | |
| Subtype | |||
| Luminal subtype | 10 | 22.7 | |
| HER-2 subtype | 22 | 50.0 | |
| Triple-negative subtype | 12 | 27.3 | |
| Adjuvant chemotherapy | 33 | 80.5 | |
| Adjuvant endocrine therapy | 13 | 32.5 | |
| Adjuvant trastuzumab | 4 | 10.0 | |
| median time to progression (months) | 18.5 | ||
| Range | 0–89 | ||
| Visceral metastases | 17 | 38.6 | |
| Brain as only site of metastatic disease | 22 | 50 | |
| Median metastatic sites | 1 | ||
| Range | 1–6 | ||
| Lung | 6 | 13.6 | |
| Liver | 15 | 34.1 | |
| Bones | 11 | 25.0 | |
| Lymph nodes | 6 | 13.6 | |
| Soft tissue | 4 | 9.1 | |
| Skin | 0 | 0 | |
| Others | 1 | 2.3 | |
| Median OS from first diagnosis (months) | 29 | ||
| Range | 0–121 | ||
| Median OS from diagnosis of metastatic disease (months) | 9 | ||
| Range | 0–50 | ||
| Median OS from diagnosis of BM (months) | 9 | ||
| Range | 0–50 | ||
Abbreviations: CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease; BM=brain metastases; OS=overall survival.
Characteristics grading, staging, subtype are from time point of first diagnosis. Characteristics metastatic sites are from time point of diagnosis of brain metastases.